The role of allogeneic transplantation in high-risk acute myelogenous leukemia (Q35903540)

11 August 2017

1 reference

title

The role of allogeneic transplantation in high-risk acute myelogenous leukemia (English)

1 reference

11 August 2017

1 reference

Drobyski WR

1

1 reference

PubMed ID

15452588

11 August 2017

language of work or name

1 reference

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

18

1 reference

11 August 2017

10

1 reference

11 August 2017

1565-1568

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403482

11 August 2017

0 references

cites work

Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Grup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

New directions in natural killer cell-based immunotherapy of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a statistician's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

7 January 2021

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

7 January 2021

Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

7 January 2021

Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

7 January 2021

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403482

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403482

1 reference

PubMed ID

15452588

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15452588